Current strategies for prevention of oral manifestations of human immunodeficiency virus

Oral Surgery, Oral Medicine, Oral Pathology and Oral Radiology

Volumn 121, Issue 1, 2016, Pages 29-38

  Patton, Lauren L ^a  

^a UNIVERSITY OF NORTH CAROLINA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AIDS-RELATED OPPORTUNISTIC INFECTIONS; HUMAN; MOUTH DISEASES;

AIDS-RELATED OPPORTUNISTIC INFECTIONS; HUMANS; MOUTH DISEASES;

EID: 84962309268     PISSN: 22124403     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.oooo.2015.09.004     Document Type: Review

References (70)

1. W.V. Giannobile Our duty to promote global oral health J Dent Res 92 2013 573 574
2. P.E. Petersen Policy for prevention of oral manifestations in HIV/AIDS: the approach of the WHO Global Oral Health Program Adv Dent Res 19 2006 17 20
3. M. Coogan, and S. Challacombe The mouth and AIDS: the global challenge J Dent Res 90 2011 397 398
4. M.I. Ryder, W. Nittayananta, M. Coogan, D. Greenspan, and J.S. Greenspan Periodontal disease in HIV/AIDS Periodontol 2000 60 2012 78 97
5. EC-Clearinghouse on Oral Problems Related to HIV Infection and WHO Collaborating Centre on Oral Manifestations of the Immunodeficiency Virus Classification and diagnostic criteria for oral lesions in HIV infection J Oral Pathol Med 22 1993 289 291
6. J.S. Greenspan, C.E. Barr, J.J. Sciubba, and J.R. Winkler Oral manifestations of HIV infection. Definitions, diagnostic criteria, and principles of therapy. The U.S.A. Oral AIDS Collaborative Group Oral Surg Oral Med Oral Pathol 73 1992 142 144
7. F.J. Ramos-Gomez, C. Flaitz, P. Catapano, P. Murray, A.R. Milnes, and A. Dorenbaum Classification, diagnostic criteria, and treatment recommendations for orofacial manifestations in HIV-infected pediatric patients. Collaborative Workgroup on Oral Manifestations of Pediatric HIV Infection J Clin Pediatr Dent 23 1999 85 96
8. C.H. Shiboski, L.L. Patton, J.Y. Webster-Cyriaque, and et al. The Oral HIV/AIDS Research Alliance: updated case definitions of oral disease endpoints J Oral Pathol Med 38 2009 481 488
9. L.L. Patton, V. Ramirez-Amador, G. Anaya-Saavedra, W. Nittayananta, M. Carrozzo, and K. Ranganathan Urban legends series: oral manifestations of HIV infection Oral Dis 19 2013 533 550
10. I.M. Tamí-Maury, J.H. Willig, P.E. Jolly, and et al. Prevalence, incidence, and recurrence of oral lesions among HIV-infected patients on HAART in Alabama: a two-year longitudinal study South Med J 104 2011 561 566
11. J.D. Shulman, M.M. Beach, and F. Rivera-Hidalgo The prevalence of oral mucosal lesions in U.S. adults: data from the Third National Health and Nutrition Examination Survey, 1988-1994 J Am Dent Assoc 135 2004 1279 1286
12. W.V. Giannobile, K.S. Kornman, and R.C. Williams Personalized medicine enters dentistry: what might this mean for clinical practice? J Am Dent Assoc 144 2013 874 876
13. I. Garcia, R. Kuska, and M.J. Somerman Expanding the foundation for personalized medicine: implications and challenges for dentistry J Dent Res 92 2013 S3 S10
14. A.R. Tappuni, and G.J. Fleming The effect of antiretroviral therapy on the prevalence of oral manifestations in HIV-infected patients: a UK study Oral Surg Oral Med Oral Pathol Oral Radiol Endod 92 2001 623 628
15. L.L. Patton Sensitivity, specificity, and positive predictive value of oral opportunistic infections in adults with HIV/AIDS as markers of immune suppression and viral burden Oral Surg Oral Med Oral Pathol Oral Radiol Endod 90 2000 182 188
16. Panel on Opportunistic Infections in HIV-Infected Adults and Adolescents. Guidelines for the prevention and treatment of opportunistic infections in HIV-infected adults and adolescents: recommendations from the Centers for Disease Control and Prevention, the National Institutes of Health, and the HIV Medicine Association of the Infectious Diseases Society of America (pp. 1-407). Available at: http://aidsinfo.nih.gov/contentfiles/lvguidelines/adult-oi.pdf. Accessed March 25, 2015.
17. R. Cauda, E. Tacconelli, M. Tumbarello, and et al. Role of protease inhibitors in preventing recurrent oral candidosis in patients with HIV infection: a prospective case-control study J Acquir Immune Defic Syndr 21 1999 20 25
18. P. Diz Dios, A. Ocampo, C. Miralles, I. Otero, I. Iglesias, and N. Rayo Frequency of oropharyngeal candidiasis in HIV-infected patients on protease inhibitor therapy Oral Surg Oral Med Oral Pathol Oral Radiol Endod 87 1999 437 441
19. C. Calugi, A. Guarna, and A. Trabocchi Insight into the structural similarity between HIV protease and secreted aspartic protease-2 and binding mode analysis of HIV-Candida albicans inhibitors J Enzyme Inhib Med Chem 28 2013 936 943
20. L.L. Patton, A.J. Bonito, and D.A. Shugars A systematic review of the efficacy and effectiveness of antifungal drugs in the prevention and treatment of oropharyngeal candidiasis in HIV-positive patients Oral Surg Oral Med Oral Pathol Oral Radiol Endod 92 2001 170 179
21. L. Baccaglini, J.C. Atkinson, L.L. Patton, M. Glick, G. Ficarra, and D.E. Peterson Management of oral lesions in HIV-positive patients Oral Surg Oral Med Oral Pathol Oral Radiol Endod 103 2007 S50.e1 S50.e23
22. J.A. Ship, A. Vissink, and S.J. Challacombe Use of prophylactic antifungals in the immunocompromised host Oral Surg Oral Med Oral Pathol Oral Radiol Endod 103 2007 S6.e1 S6.e14
23. A.M. Hegarty, S.I. Chaudhry, and T.A. Hodgson Oral healthcare for HIV-infected patients: an international perspective Expert Opin Pharmacother 9 2008 387 404
24. E.D. Pienaar, T. Young, and H. Holmes Interventions for the prevention and management of oropharyngeal candidiasis associated with HIV infection in adults and children Cochrane Database Syst Rev 2010 CD003940
25. Panel on Opportunistic Infections in HIV-Exposed and HIV-Infected Children. Guidelines for the Prevention and Treatment of Opportunistic Infections in HIV-Exposed and HIV-Infected Children. Department of Health and Human Services. Available at: http://aidsinfo.nih.gov/contentfiles/lvguidelines/oi-guidelines-pediatrics.pdf. Accessed: March 25, 2015.
26. O. Lortholary, G. Petrikkos, M. Akova, and et al. ESCMID∗guideline for the diagnosis and management of Candida diseases 2012: patients with HIV infection or AIDS Clin Microbiol Infect 18 2012 68 77
27. M. Nelson, D. Dockrell, S. Edwards, and et al. British HIV Association and British Infection Association guidelines for the treatment of opportunistic infection in HIV-seropositive individuals 2011 HIV Med 12 2011 1 140
28. W. Nittayananta, T.A. DeRouen, P. Arirachakaran, and et al. A randomized clinical trial of chlorhexidine in the maintenance of oral candidiasis-free period in HIV infection Oral Dis 14 2008 665 670
29. A. Barasch, M.M. Safford, I. Dapkute-Marcus, and D.H. Fine Efficacy of chlorhexidine gluconate rinse for treatment and prevention of oral candidiasis in HIV-infected children: a pilot study Oral Surg Oral Med Oral Pathol Oral Radiol Endod 97 2004 204 207
30. W. Nittayananta, K. Pangsomboon, P. Panichayupakaranant, and et al. Effects of lawsone methyl ether mouthwash on oral Candida in HIV-infected subjects and subjects with denture stomatitis J Oral Pathol Med 42 2013 698 704
31. M. Patel, J.A. Shackleton, M.M. Coogan, and J. Galpin Antifungal effect of mouth rinses on oral Candida counts and salivary flow in treatment-naïve HIV-infected patients AIDS Patient Care STDS 22 2008 613 618
32. J.F. Hilton, L.A. MacPhail, L. Pascasio, and et al. Self-care intervention to reduce oral candidiasis recurrences in HIV-seropositive persons: A pilot study Community Dent Oral Epidemiol 32 2004 190 200
33. G.M. McCarthy, I.D. Mackie, J. Koval, H.S. Sandhu, and T.D. Daley Factors associated with increased frequency of HIV-related oral candidiasis J Oral Pathol Med 20 1991 332 336
34. G.M. McCarthy Host factors associated with HIV-related oral candidiasis. A review Oral Surg Oral Med Oral Pathol 73 1992 181 186
35. A. Chattopadhyay, and L.L. Patton Smoking as a risk factor for oral candidiasis in HIV-infected adults J Oral Pathol Med 42 2013 302 308
36. D. Greenspan, E. Komaroff, M. Redford, and et al. Oral mucosal lesions and HIV viral load in the Women's Interagency HIV Study (WIHS) J Acquir Immune Defic Syndr 25 2000 44 50
37. L.S. Jacob, C.M. Flaitz, C.M. Nichols, and M.J. Hicks Role of dentinal carious lesions in the pathogenesis of oral candidiasis in HIV infection J Am Dent Assoc 129 1998 187 194
38. A.L. Witzel, F. Pires Mde, M.L. de Carli, G.D. Rabelo, T.B. Nunes, and F.R. da Silveira Candida albicans isolation from buccal mucosa of patients with HIV wearing removable dental prostheses Int J Prosthodont 25 2012 127 131
39. L.F. Perezous, G.C. Stevenson, C.M. Flaitz, M.E. Goldschmidt, R.L. Engelmeier, and C.M. Nichols The effect of complete dentures with a metal palate on Candida species growth in HIV-infected patients J Prosthodont 15 2006 306 315
40. A.A. Dahlan, C.W. Haveman, G. Ramage, J.L. Lopez-Ribot, and S.W. Redding Sodium hypochlorite, chlorhexidine gluconate, and commercial denture cleansers as disinfecting agents against Candida albicans: an in vitro comparison study Gen Dent 59 2011 e224 e229
41. H. Rahimi, T. Mara, J. Costella, M. Speechley, and R. Bohay Effectiveness of antiviral agents for the prevention of recurrent herpes labialis: a systematic review and meta-analysis Oral Surg Oral Med Oral Pathol Oral Radiol 113 2012 618 627
42. C.S. Miller, L.L. Cunningham, J.E. Lindroth, and S.A. Avdiushko The efficacy of valacyclovir in preventing recurrent herpes simplex virus infections associated with dental procedures J Am Dent Assoc 135 2004 1311 1318
43. J. Aberg, and W. Powderly HIV: primary and secondary prophylaxis for opportunistic infections Clin Evid (Online) 2010 2010 0908
44. J.F. Rooney, Y. Bryson, M.L. Mannix, and et al. Prevention of ultraviolet-light-induced herpes labialis by sunscreen Lancet 338 1991 1419 1422
45. D.M. Walling, C.M. Flaitz, and C.M. Nichols Epstein-Barr virus replication in oral hairy leukoplakia: response, persistence, and resistance to treatment with valacyclovir J Infect Dis 188 2003 883 890
46. L.J. Conley, T.J. Bush, S.P. Buchbinder, K.A. Penley, F.N. Judson, and S.D. Holmberg The association between cigarette smoking and selected HIV-related medical conditions AIDS 10 1996 1121 1126
47. A.C. Moorman, S.D. Holmberg, S.I. Marlowe, and et al. Changing conditions and treatments in a dynamic cohort of ambulatory HIV patients: The HIV outpatient study (HOPS) Ann Epidemiol 9 1999 349 357
48. A. Chattopadhyay, D.J. Caplan, G.D. Slade, D.C. Shugars, H.-C. Tien, and L.L. Patton Risk indicators for oral candidiasis and oral hairy leukoplakia in HIV-infected adults Community Dent Oral Epidemiol 33 2005 35 44
49. P.G. Robinson, A. Sheiham, S.J. Challacombe, M.W. Wren, and J.M. Zakrzewska Gingival ulceration in HIV infection. A case series and case control study J Clin Periodontol 25 1998 260 267
50. J.B. Brown, D. Rosenstein, J. Mullooly, M. O'Keeffe Rosetti, S. Robinson, and G. Chiodo Impact of intensified dental care on outcomes in human immunodeficiency virus infection AIDS Patient Care STDS 16 2002 479 486
51. D. Hofer, C.H. Hämmerle, M. Grassi, and N.P. Lang Long-term results of supportive periodontal therapy (SPT) in HIV-seropositive and HIV-seronegative patients J Clin Periodontol 29 2002 630 637
52. C.S. Tsang, and L.P. Samaranayake Immune reconstitution inflammatory syndrome after highly active antiretroviral therapy: a review Oral Dis 16 2010 248 256
53. V.A. Ramírez-Amador, E. Espinosa, I. González-Ramírez, G. Anaya-Saavedra, C.E. Ormsby, and G. Reyes-Terán Identification of oral candidosis, hairy leukoplakia and recurrent oral ulcers as distinct cases of immune reconstitution inflammatory syndrome Int J STD AIDS 20 2009 259 261
54. A.M. Geretti, and T. Doyle Immunization for HIV-positive individuals Curr Opin Infect Dis 23 2010 32 38
55. D.C. Beachler, A.G. Abraham, M.J. Silverberg, and et al. Incidence and risk factors of HPV-related and HPV-unrelated head and neck squamous cell carcinoma in HIV-infected individuals Oral Oncol 50 2014 1169 1176
56. R. Herrero, W. Quint, A. Hildesheim, and et al. Reduced prevalence of oral human papillomavirus (HPV) 4 Years after bivalent HPV vaccination in a randomized clinical trial in Costa Rica PLoS One 8 2013 E68329
57. P.L. McCormack, and E.A. Joura Quadrivalent human papillomavirus (types 6, 11, 16, 18) recombinant vaccine (Gardasil®): A review of its use in the prevention of premalignant genital lesions, genital cancer and genital warts in women Drugs 70 2010 2449 2474
58. A.R. Kreimer Prospects for prevention of HPV-driven oropharynx cancer Oral Oncol 50 2014 555 559
59. K.J. Syrjänen Annual disease burden due to human papillomavirus (HPV) 6 and 11 infections in Finland Scand J Infect Dis Suppl 107 2009 3 32
60. E. Petrosky, J.A. Bocchini Jr., S. Hariri, and et al. Use of 9-valent human papilloma virus (HPV) vaccine: updated HPV vaccination recommendations of the advisory committee on immunization practices MMWR Morb Mortal Wkly Rep 64 2015 300 304
61. J.I. Cohen, E.S. Mocarski, N. Raab-Traub, L. Corey, and G.J. Nabel The need and challenges for development of an Epstein-Barr virus vaccine Vaccine 31 2013 B194 B196
62. C. Johnston, D.M. Koelle, and A. Wald HSV-2: in pursuit of a vaccine J Clin Invest 121 2011 4600 4609
63. L.K. Dropulic, and J.I. Cohen The challenge of developing a herpes simplex virus 2 vaccine Expert Rev Vaccines 11 2012 1429 1440
64. T.T. Wu, J. Qian, J. Ang, and R. Sun Vaccine prospect of Kaposi sarcoma-associated herpesvirus Curr Opin Virol 2 2012 482 488
65. S.D. Lawn, S.T. Butera, and T.M. Folks Contribution of immune activation to the pathogenesis and transmission of human immunodeficiency virus type 1 infection Clin Microbiol Rev 14 2001 753 777
66. C.S. Marshall, A.J. Curtis, T. Spelman, and et al. Impact of HIV-associated conditions on mortality in people commencing anti-retroviral therapy in resource limited settings PLoS One 8 2013 E68445
67. O.A. González, J.L. Ebersole, and C.B. Huang Oral infectious diseases: a potential risk factor for HIV virus recrudescence? Oral Dis 15 2009 313 327
68. D.C. Shugars, L.L. Patton, S.A. Freel, and et al. Hyper-excretion of human immunodeficiency virus type 1 RNA in saliva J Dent Res 80 2001 414 420
69. S.M. Wahl, M. Redford, S. Christensen, and et al. Systemic and mucosal differences in HIV burden, immune and therapeutic responses J Acquir Immune Defic Syndr 56 2011 401 411
70. E.F. Kong, S. Kucharíková, P. Van Dijck, B.M. Peters, M.E. Shirtliff, and M.A. Jabra-Rizk Clinical implications of oral candidiasis: host tissue damage and disseminated bacterial disease Infect Immun 83 2015 604 613